A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period
- Conditions
- ovel coronavirus pneumonia (COVID-19)
- Registration Number
- ITMCTR2000003230
- Lead Sponsor
- Hubei Provincial Hospital of TCM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- Not specified
1. Patients who meet the COVID-19 diagnostic criteria and discharge standards with SARS-CoV-2 virus nucleic acid test is negative;
2. The pulmonary imaging in the last 1 week showed inflammation or fibrosis;
3. Aged 18 to 70 years old;
4. Signed informed consent.
1. History of pulmonary surgery which affected lung function;
2. Relying on mechanical ventilation to maintain lung function;
3. Complications of chronic lung disease, such as COPD;
4. Complications affecting heart function;
5. Patients with severe primary diseases may affect participation in the trial or may affect the outcome of the study by the judgment of the researcher;
6. Resting heart rate >120/min;
7. Systolic blood pressureda>180mmHgDiastolic blood pressure>100mmHg;
8. Unstable angina or myocardial infarction that occurred within the past month;
9. BMI>40;
10. Patients who are allergic constitution or allergy to multiple drug;
11. Pregnant or lactating women;
12. Handicapped who can't complete the collection of efficacy evaluation indicators;
13. Patients who have a family history of mental illness or have had a mental illness;
14. Patients who are participating in other clinical trials;
15. According to the investigator's judgment, patients who have complicated enrollment or poor compliance, which affect the efficacy and safety assessment.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Six-minute Walk Test;lung CT;
- Secondary Outcome Measures
Name Time Method GAD-7;PHQ-9;SARS-CoV-2 nucleic acid test and 2019-nCoV Antibody Test ;QQL-BREF;Clinical symptoms;Dynamic oxygen saturation;